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Introduction
Since status epilepticus (SE) is characterized by signifi-
cant short-term morbidity and mortality [6, 9, 16], 
prompt treatment institution is recommended [17, 22, 
26]. SE treatment protocols present a wide range of in-
tensities, from small doses of benzodiazepine, to combi-
nations of intravenously administered antiepileptic 
drugs, to coma induction with an appropriate anesthetic 
agent, such as barbiturates, propofol, or midazolam [17, 
22]. Each of these therapeutic approaches bears a spe-
cific risk, and it is still not clear if the risk associated 
with aggressive therapy balances the potential benefit of 
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■ Abstract  Background Status 
 epilepticus (SE) treatment ranges 
from small benzodiazepine doses 
to coma induction. For some SE 
subgroups, it is unclear how the 
risk of an aggressive therapeutic 
approach balances with outcome 
improvement. We recently devel-
oped a prognostic score (Status 
 Epilepticus Severity Score, STESS), 
relying on four outcome predictors 
(age, history of seizures, seizure 
type and extent of consciousness 
impairment), determined before 
treatment institution. Our aim was 
to assess whether the score might 
have a role in the treatment strat-
egy choice. Methods This cohort 
study involved adult patients in 
three centers. For each patient, the 
STESS was calculated before pri-
mary outcome assessment: survival 
vs. death at discharge. Its ability to 
predict survival was estimated 
through the negative predictive 
value for mortality (NPV). Strati-
fied odds ratios (OR) for mortality 
were calculated considering coma 
induction as exposure; strata were 
defined by the STESS level. Results 
In the observed 154 patients, the 
STESS had an excellent negative 
predictive value (0.97). A favorable 
STESS was highly related to sur-
vival (P < 0.001), and to return to 
baseline clinical condition in survi-
vors (P < 0.001). The combined 
Mantel-Haenszel OR for mortality 
in patients stratified after coma 
 induction and their STESS was 1.5 
(95 % CI: 0.59–3.83). Conclusion 
The STESS reliably identifies SE 
patients who will survive. Early 
 aggressive treatment could not be 
routinely warranted in patients 
with a favorable STESS, who will 
almost certainly survive their SE 
episode. A randomized trial using 
this score would be needed to con-
firm this hypothesis.
■ Key words  status epilepticus · 
prognosis · treatment · coma 
 induction · outcome
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an improved outcome. This issue seems to be relevant 
especially in complex-partial SE, in which the likelihood 
of subsequent neurological sequelae appears lower than 
after generalized convulsive or non-convulsive status in 
coma (“subtle status”) [2, 10, 13, 14, 29].
SE outcome predictors might be useful in determin-
ing treatment strategy for a given patient. In a prelimi-
nary approach, we recently developed a simple clinical 
prognostic score (for which we propose the name of Sta-
tus Epilepticus Severity Score, or STESS), in order to 
predict survival, before treatment institution, of adult 
patients presenting with SE; it was validated on a small 
prospective cohort of 34 patients [20]. 
The main aim of this study was to assess the potential 
utility of the STESS in the choice of SE treatment strat-
egy by comparing outcomes of patients with and with-
out coma induction, stratified according to their STESS. 
We also analyzed whether subjects having a favorable 
score would additionally benefit from therapeutic 
coma.
Methods
■ Design and data collection
This was a prospective observational study carried out at three Uni-
versity Hospitals (Centre Hospitalier Universitaire Vaudois, CHUV, 
Lausanne, Switzerland; Brigham and Women’s Hospital, BWH, and 
Massachusetts General Hospital, MGH, Boston, MA, USA). The cohort 
consisted of patients older than 16 years presenting during different 
time frames in the three participating centers: April 2006–June 2007 
at CHUV, July 2004–March 2007 (with an interruption between Octo-
ber 2005 and May 2006, when only sporadic patients were assessed) 
at BWH, and December 2006–July 2007 at MGH. Apart from the tran-
sitory interruption period at BWH, subjects were recorded consecu-
tively. The first 34 patients at BWH overlap with our previous report 
[20]. Clinicians in charge of the data collection at each site recorded 
all needed variables on patients’ admission, before therapeutic inter-
ventions; they were not primarily involved in treatment choice. The 
STESS was calculated shortly after treatment institution (but before 
outcome assessment); therefore, its value did not influence the choice 
of treatment strategy, nor did knowledge of the outcome bias the 
score. 
■ STESS description
This score relies on the assessment of age (0 or 2 points, cutoff at 65), 
previous history of seizures (1 point if negative, as a surrogate for 
acute etiology), seizure type (0, 1 or 2 points), and extent of conscious-
ness impairment (1 point if stuporous or comatose) (Table 1); a score 
of 0–2 is defined as favorable, indicating low risk of death. Its rationale 
and preliminary validation have been previously described [20]. 
■ Definitions and variables
As in our previous work [19, 20], we defined SE as ongoing seizures, 
or repetitive seizures without intercurrent normalization of con-
sciousness or return to baseline, for at least 30 minutes. This widely 
accepted definition for epidemiological studies allows a comparison 
with previous works on SE treatment. All patients had at least a rou-
tine EEG within 24 hours of admission, and follow-up recordings in-
cluding EEG monitoring were performed in all patients failing to 
awake after clinical convulsion subsided. Subjects with SE from cere-
bral anoxia were excluded, owing to the almost invariably dismal 
prognosis related to this condition. In addition to demographic char-
acteristics, we identified previous history of seizures, seizure semiol-
ogy focusing on the worst manifestation before treatment (in de-
scending order of gravity: nonconvulsive SE in coma, generalized 
convulsive, complex partial, myoclonic or absence or simple partial), 
time between seizure onset and institution of the first specific treat-
ment (dichotomized as < or ≥ 1 h), and SE etiology (according to ILAE 
criteria [1], classified as acute symptomatic, remote symptomatic, 
progressive symptomatic, and idiopathic/cryptogenic). As we have 
previously proposed [19], we also labeled etiologies as potentially fa-
tal, if having the risk of leading to death within days-weeks unless 
specifically treated, even in the absence of SE. Level of consciousness 
before treatment was categorized as alert, somnolent (arousable and 
responsive) or confused, stuporous (arousable but non-responsive), 
and comatose (non-arousable). Outcome was assessed at hospital dis-
charge (dead, alive but substantially impaired relative to baseline 
clinical condition, or returned to baseline). 
■ Statistical analysis
Sensitivity, specificity, positive predictive value, and negative predic-
tive value (NPV) of the STESS were estimated with their Wilson’s bi-
nomial 95 % CI. Unweighted accuracy was calculated as the average of 
sensitivity and specificity. Chi square or Fisher exact tests were used, 
as needed, to compare categorical variables of interest between sur-
viving and dead patients, and among the three centers, whereas t-tests 
or one-way ANOVA were applied for continuous variables. Stratified 
OR for mortality were estimated. Exposed patients were those with 
coma induction, and strata were defined by the STESS level (favorable 
Features STESS
Consciousness Alert or somnolent/confused
Stuporous or comatose
0
1
Worst seizure type Simple-partial, complex-partial, absence, myoclonic*
Generalized-convulsive 
Nonconvulsive status epilepticus in coma
0
1
2
Age < 65 years
≥ 65 years
0
2
History of previous seizures Yes
No or unknown
0
1
Total 0–6
* complicating idiopathic generalized epilepsy
Table 1  Status Epilepticus Severity Score (STESS), 
modified after [19]. A favorable score is 0–2
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vs. unfavorable). Mantel-Haenszel χ2 tests were used to test homoge-
neity of OR across strata. A backward stepwise logistic regression 
model with mortality as dependent variable was constructed using 
variables with p < 0.20 in univariate analysis. All calculations were 
performed with a Stata software package, version 9.
Results
The cohort consisted of 154 adult patients (CHUV 67, 
BWH 61, MGH 26). Demographic and clinical features, 
classified by outcome, are shown in Table 2. There were 
1 generalized myoclonic SE (complicationg juvenile 
myoclonic epilepsy), 3 absence SE, 21 simple-partial SE, 
57 complex-partial SE, 53 generalized convulsive SE, and 
19 non-convulsive SE with coma. The high prevalence of 
simple-partial and complex-partial SE probably ex-
plains the long delay before treatment in the majority of 
our patients. In univariate analysis, age (as a continuous 
variable), acute symptomatic etiology, potentially fatal 
etiology, absence of previous seizures, generalized con-
vulsive or non-convulsive SE in coma, marked con-
sciousness impairment, and coma induction were asso-
ciated with higher mortality (p < 0.05), but gender and 
treatment delay were not. In the final multivariable lo-
gistic regression, age, absence of history of previous sei-
zures, potentially fatal etiology, and seizure type were 
determined to be independent risk factors for mortality 
(Table 3). This model had an excellent goodness of fit 
(Hosmer-Lemshow test for 10 groups: P = 0.73). 
Each variable was compared among the three centers: 
gender (P = 0.676, χ2), age (P = 0.816, ANOVA), acute 
symptomatic etiology (P = 0.489, χ2), potentially fatal 
etiology (P = 0.133, χ2), history of previous seizures 
(P = 0.458, χ2), seizure type (P = 0.187, χ2), extent of con-
sciousness impairment (P = 0.433, χ2), and treatment 
delay (P = 0.793, χ2) were not different. Although mortal-
ity (p = 0.308, χ2) and STESS severity (p = 0.793, χ2) were 
also similar, therapeutic coma was significantly less fre-
quent at CHUV (12 %) than at the two Boston hospitals 
(BWH 36 %, MGH 36 %, P = 0.004, χ2). 
Table 4 summarizes the validity of STESS in assessing 
mortality risk in this multicenter cohort. The score had 
a very high negative predictive value for fatal outcome 
(0.97), with a narrow CI. A favorable STESS (0–2) was 
consistently related both to survival (97 % if favorable 
STESS vs. 61 % if unfavorable STESS, P < 0.001, Fisher) 
and likelihood to return to baseline clinical condition in 
surviving patients (81 % if favorable STESS vs. 35 % if 
unfavorable STESS, P < 0.001, χ2). We also assessed the 
STESS performance on the subgroup of 57 patients with 
complex-partial SE: all 33 subjects with favorable score 
Alive Dead P Test
121 (79 %) 33 (21 %)
Gender (F)  62 (51 %) 15 (45 %)    0.556 χ2
Age (mean ± SD)  57.2 ± 19.0 65.1 ± 18.3    0.035 t
Acute symptomatic etiology [1]  63 (52 %) 24 (73 %)    0.034 χ2
Potentially fatal etiology [19]  53 (44 %) 28 (85 %) < 0.001 χ2
History of previous seizures  74 (61 %)  6 (18 %) < 0.001 χ2
Seizure type GC or NCSEC  48 (40 %) 24 (73 %)    0.001 χ2
Consciousness before treatment
 Alert  15 (12 %)  2 (6 %)
 Somnolent/confused  47 (39 %)  5 (15 %)
 Stuporous  38 (31 %) 13 (39 %)
 Comatose  22 (18 %) 13 (39 %)    0.012 FET
Treatment after ≥ 1 h  90 (74 %) 26 (79 %)    0.603
Coma induction for treatment  26 (21 %) 13 (39 %)    0.036
GC generalized convulsive; NCSEC nonconvulsive status epilepticus in coma; FET Fisher’s exact test
Table 2  Variables of interests as compared to of 
mortality in the whole cohort (154 patients)
Table 3  Logisitc regression model for variables associated with mortality
OR 95 % CI p
Age (mean ± SD) 1.03 1.00–1.06 0.045
Potentially fatal etiology [19] 4.14 1.37–12.49 0.012
History of previous seizures 0.23 0.08–0.65 0.006
Seizure type GC or NCSEC 5.80 2.11–15.90 0.001
GC generalized convulsive; NCSEC nonconvulsive status epilepticus in coma 
Table 4  STESS characteristics related to mortality in the 154 patients. 95 % CI was 
calculated using a Wilson binomial distribution 
Alive Dead Total
Score 0–2 (favorable)  72 (97 %)  2 (3 %)  74
Score 3–6 (unfavorable)  49 (61 %) 31 (39 %)  80
Total 121 (79 %) 33 (21 %) 154
Sensitivity: 0.94 (95 % CI: 0.804–0.983)
Specificity: 0.60 (95 % CI: 0.506–0.678)
Positive predictive value: 0.39 (95 % CI: 0.288–0.497)
Negative predictive value: 0.97 (95 % CI: 0.907–0.993)
Unweighted accuracy: 0.767
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survived, whereas 7 out of 24 with a score greater than 2 
died (P = 0.01, Fisher).
To investigate whether the decision to induce coma 
should be related to STESS, we estimated the mortality 
in the four groups defined by crossing the variables ST-
ESS and coma induction; the results are given in Table 5. 
In the group with favorable STESS, 2/63 died in the group 
unexposed to coma, versus 0/11 in the exposed group, 
while among subjects with unfavorable STESS, 35 % 
(18/52) died in the unexposed group compared with 
46 % (13/28). The combined Mantel-Haenszel OR for 
mortality was 1.5 (95 % CI 0.59–3.83). The hypothesis of 
homogeneity of strata was not rejected by the Mantel-
Haenszel test (p = 0.4). Thus, the survival was not for-
mally found to be different depending on coma induc-
tion, regardless of the STESS score. 
Discussion
The first important finding of this prospective study is 
that the STESS is an excellent predictor of outcome: pa-
tients with a low score have a reliably good prognosis for 
survival, as well as for return to baseline clinical condi-
tion (Table 4); this confirms our previous observations 
based on retrospective data [20]. STESS relies on proven 
SE predictors and is very easy to calculate in an emer-
gency setting [20], requiring less than a minute after pa-
tient admission. Consciousness represents a critical 
item, which (as in our case study) should be assessed 
before administration of benzodiazepines (mostly by 
personal paramedics’ reports). Inclusion of an etiology 
item would certainly enhance its value, but very often 
the SE cause can only be determined after examinations 
such as brain imaging and laboratory work-up (includ-
ing CSF analysis), requiring a delay up to several hours 
or days that may prove critical for the therapeutic man-
agement. We therefore developed this score using “pre-
vious seizures” as an etiology surrogate; this informa-
tion, indeed, is more likely to be available on admission. 
Although the score was calculated after treatment insti-
tution, the knowledge of its clinical variables may have 
influenced the treatment strategy; this potential bias is 
inherent to the observational study design. However, the 
fact that the observations were carried out in three dif-
ferent hospitals on two continents reinforces these re-
sults. The reliability of predicting survival is the most 
robust benefit of using the STESS: its very high NPV (the 
fraction of surviving patients having a favorably low 
score) reflects a very low rate of falsely predicted sur-
vival. Conversely, STESS does not have a good positive 
predictive value for death, therefore it should not be 
used to justify medical support withdrawal.
After adjustment for baseline state (measured with 
STESS), mortality was not found to be associated with 
coma induction (OR = 1.5 95 % CI 0.59 – 3.83). However, 
our study was observational, and neurologists at the dif-
ferent hospitals did not have a uniform treatment strat-
egy, even if each center uses a SE therapy protocol in 
accordance with generally accepted guidelines [17]. Al-
though we did not find any marked difference between 
our three hospitals regarding age, gender, etiology, 
 seizure type, consciousness impairment, latency of SE 
treatment, and mortality (and, in general, the outcome 
predictors’ profile reflected by the STESS) by institution, 
therapeutic coma frequency differed between CHUV 
and the two Boston hospitals, being less frequent in the 
former. If pharmacologic coma had a major effect on 
mortality, the latter would likely differ according to its 
changing prevalence; this was not observed among the 
three participating centers. Indeed, Table 5 suggests that 
patients suffering from SE having a favorable outcome 
profile on admission do not need coma, as almost all do 
well without it. Although, owing to the sample size, a 
possible slight benefit cannot be excluded (3 % mortal-
ity in the untreated group versus 0 % in the treated, non-
significant), mortality is impressively low compared to 
that of the group with unfavorable score. 
This represents, in our opinion, an important issue to 
be considered for the choice of SE treatment strategy. 
Indeed, the debate among experts focusing on whether 
to treat aggressively, i.e., using prompt coma induction 
in case of SE refractoriness, is mainly limited to patients 
with complex-partial SE [10, 13, 14]; conversely, there is 
an implicit consensus regarding subjects suffering from 
generalized convulsive SE [17, 22]. We showed that the 
STESS is also reliable in the complex-partial SE sub-
group of patients, in whom potential complications aris-
ing from prolonged use of mechanical ventilation and 
intensive-care unit stay, such as hypotension requiring 
vasopressors, immunosuppression, gastroparesis, deep 
vein thrombosis, respiratory failure, and potentially fatal 
Alive Dead P Test
STESS 0–2 (favorable): 74 patients
 Coma induction – 61 (97 %)  2 (3 %)
 Coma induction + 11 (100 %)  0 1.000 Fisher
STESS 3–6 (unfavorable): 80 patients
 Coma induction – 34 (65 %) 18 (35 %)
 Coma induction + 15 (54 %) 13 (46 %) 0.301 Fisher
Table 5  Mortality depending on STESS and coma 
induction for SE treatment
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metabolic disturbances [4, 12, 30], might exceed the ben-
efit of a rapid SE control. Moreover, generous use of ben-
zodiazepines in older SE patients, leading to marked 
consciousness impairment, has been shown to worsen 
prognosis [21]. Indeed, it is debatable whether prolonged 
complex partial seizures in humans induce permanent 
structural neurological damage [2, 10, 13, 14, 29], as op-
posed to generalized convulsive SE forms, in which 
damage in the limbic structures has been confirmed 
both pathologically and radiologically [7, 8, 18, 23]. The 
fact that patients with high STESS who were treated with 
coma had a somewhat higher mortality than those who 
were not treated aggressively (Table 5) likely reflects the 
common policy of inducing coma especially in subjects 
with a more ominous prognosis, and, in our opinion, 
does not argue in favor of an independent deleterious 
effect of coma induction. 
Our cohort of 154 patients, recruited prospectively 
on both sides of the Atlantic in three tertiary referral 
hospitals, is comparable to previously reported SE series 
in terms of demographics and mortality [6, 9, 11, 15, 16, 
19]. Results of multivariable logistic regression, showing 
that age, etiology (for which absence of previous sei-
zures might be viewed as a surrogate) and seizure type 
are independently related to mortality at hospital dis-
charge, replicates previous findings [5, 9, 16, 19, 24, 25]. 
In this dataset, on the other hand, extent of conscious-
ness impairment was not a predictor of survival, contra-
dicting our previous findings in a retrospective adult SE 
series [19]. Differences in variables’ assessment between 
prospective and retrospective designs and the likely in-
teraction between consciousness and seizure type prob-
ably account for this discrepancy. This also suggests that, 
although published prospective SE series have a sample 
size comparable to ours [6, 9, 15] or smaller [27, 28], 
much larger databases should be used in order to better 
explore SE predictors. The consecutive recruitment ex-
perienced a transitory interruption at BWH, due to per-
sonnel shortage. We estimated that about 10 patients 
were missed in our database. However, this occurred in-
dependently from their clinical situation. Furthermore, 
this study being primarily aimed at verifying the useful-
ness of a score and not at estimating an incidence, we do 
not believe that this issue biased our results.
Another interesting issue is confirmation of the pre-
viously reported usefulness of a modified etiology cat-
egorization [19]. Indeed, in our model, “potentially fatal 
etiology” appears better suited to predict bad outcome 
as compared to the classically used “acute symptomatic” 
classification [1]. The latter, proposed in detail in 1993, 
raises problems especially regarding patients with SE 
following antiepileptic drug withdrawal or minor inter-
current infections, which are categorized as “acute 
symptomatic,” but usually do not have a high mortality 
risk; conversely, malignant tumors may have a major im-
pact on short-term prognosis of SE [3], yet they are of-
ficially labeled as “progressive symptomatic”. 
We considered mortality as primary outcome. This 
represents a potential limitation, since it may not only 
reflect the underlying clinical situation, but also the like-
lihood of care withdrawal that can be different among 
centers and cultures. Furthermore, we did not control 
for more subtle variables, such as the type and dose of 
administered agents. 
In conclusion, our prospective study suggests that 
STESS can represent a useful tool in assessing the grav-
ity of SE episodes and that immediate aggressive treat-
ment, bearing inherent risks, might possibly be avoided 
in the majority of patients with a low score, who will 
almost certainly survive their SE episode, and likely re-
turn to clinical baseline. Since the observational nature 
of this study does not allow to formally rule out that 
variables that were not assessed may influence the out-
come or underlie a benefit of coma induction even in 
patients with a favorable STESS, it would be particularly 
useful to confirm these observations studying patients 
(especially those with complex-partial SE) in a trial, us-
ing this score as an instrument to evaluate the patients 
at baseline. 
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